Skip to content
About
About
Join The Team
Management Team
Pipeline
Technology
Technology
Tavo
VLA
Combination Approach
Publications
Partnering
Patients
Patients
Resources
Together Against Cancer
Investors
Media & Videos
Contact
Menu Toggle
About
Menu Toggle
About
Join The Team
Management Team
Pipeline
Technology
Menu Toggle
Technology
Tavo
VLA
Combination Approach
Publications
Partnering
Patients
Menu Toggle
Patients
Resources
Together Against Cancer
Investors
Media & Videos
Contact
PIPELINE
PIPELINE
REGIMEN
TRIAL
INDICATION
PARTNER
PHASE 1
PHASE 2
PIVOTAL
Pipeline
TAVO™
REGIMEN
TAVO + pembrolizumab
TRIAL
KEYNOTE-695
INDICATION
Advanced Melanoma
PARTNER
PHASE 1
PHASE 2
PIVOTAL
REGIMEN
TAVO + pembrolizumab
TRIAL
KEYNOTE-890
INDICATION
Triple Negative
Breast Cancer (TNBC)
PARTNER
PHASE 1
PHASE 2
PIVOTAL
REGIMEN
TAVO + SARS-CoV-2
spike glycoprotein
TRIAL
Phase 1, open-label study
INDICATION
COVID-19 Vaccine
PARTNER
PHASE 1
PHASE 2
PIVOTAL
REGIMEN
TAVO + epacadostat +
pembrolizumab
TRIAL
OMS-131
(Investigator sponsored study)
INDICATION
Squamous cell
carcinoma head and
neck (SCCHN) cancer
PARTNER
PHASE 1
PHASE 2
PIVOTAL
REGIMEN
TAVO +
nivolumab
TRIAL
OMS-104
(Investigator Sponsored Study)
INDICATION
Neoadjuvant for
operable
locally/regionally
advanced melanoma
PARTNER
PHASE 1
PHASE 2
PIVOTAL
REGIMEN
TAVO +
HER2-plasmid
vaccine
TRIAL
Proof of
Concept Study
INDICATION
HER2+ Breast
Cancers
PARTNER
REGIMEN
TAVO + CXCL9
TRIAL
Proof of
Concept Study
INDICATION
Solid tumors
PARTNER
Learn more about our current clinical trials.
LEARN MORE
